Published in Prostate on November 17, 2010
First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics (2015) 0.92
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC Cancer (2014) 0.83
Prostate cancer: the need for biomarkers and new therapeutic targets. J Zhejiang Univ Sci B (2014) 0.82
Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion. J Biol Chem (2015) 0.80
Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer. Biomed Res Int (2014) 0.78
Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype. Oncotarget (2015) 0.77
Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes. PLoS One (2014) 0.76
PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives. Clin Transl Imaging (2016) 0.75
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications. PLoS One (2015) 0.75
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int (2006) 3.39
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 3.37
Plasminogen activation and cancer. Thromb Haemost (2005) 2.21
Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J (2005) 2.12
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol (2008) 1.74
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer (2009) 1.66
Determinants of participation in colorectal cancer screening with faecal occult blood testing. J Public Health (Oxf) (2009) 1.62
uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J Cell Biol (2003) 1.60
Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer (2011) 1.53
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. Urology (2012) 1.53
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer (2005) 1.48
Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study. BJU Int (2013) 1.46
Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J (2006) 1.42
[Screening for prostate cancer--what does the evidence show?]. Ugeskr Laeger (2007) 1.41
[Cryotherapy of prostatic cancer]. Ugeskr Laeger (2011) 1.39
Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. Oncogene (2003) 1.35
The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res (2013) 1.35
Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer (2007) 1.32
Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation. J Biol Chem (2007) 1.25
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate (2006) 1.24
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer (2007) 1.24
Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol (2010) 1.24
uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. Exp Cell Res (2004) 1.23
High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr (2005) 1.21
High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat (2003) 1.21
Brain energy metabolism and blood flow differences in healthy aging. J Cereb Blood Flow Metab (2012) 1.20
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology (2008) 1.18
Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers (2008) 1.18
The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. Cell Stem Cell (2007) 1.15
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology (2009) 1.14
uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets (2011) 1.12
Normalization in PET group comparison studies--the importance of a valid reference region. Neuroimage (2008) 1.12
Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells. Int J Cancer (2002) 1.12
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer (2005) 1.12
Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study. Lung Cancer (2011) 1.11
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol (2002) 1.10
Active surveillance for clinically localized prostate cancer--a systematic review. J Surg Oncol (2014) 1.09
MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res (2006) 1.08
Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis (2005) 1.08
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res (2008) 1.08
Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites. Protein Expr Purif (2004) 1.07
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res (2002) 1.07
Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis (2005) 1.06
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol (2003) 1.05
Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol (2006) 1.04
Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev (2008) 1.01
Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry. Biochemistry (2004) 1.01
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res (2007) 1.00
Prostate cancer in Denmark 1978-2009--trends in incidence and mortality. Acta Oncol (2012) 1.00
Screening for colorectal cancer: possible improvements by risk assessment evaluation? Scand J Gastroenterol (2011) 0.99
A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development (2003) 0.98
Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer (2009) 0.97
Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas (2012) 0.97
Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. Clin Chim Acta (2007) 0.96
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol (2013) 0.96
A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol (2011) 0.96
Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor. Biochem J (2004) 0.96
Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol (2010) 0.96
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene (2003) 0.95
Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res (2007) 0.93
Inguinal hernia in stage M0 prostate cancer: a comparison of incidence in men treated with and without radical retropubic prostatectomy--an analysis of 1105 patients. Urology (2005) 0.93
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model. Mol Cancer Ther (2008) 0.92
Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Dan Med J (2013) 0.92
Validation of epithelial ovarian cancer and fallopian tube cancer and ovarian borderline tumor data in the Danish Gynecological Cancer Database. Acta Obstet Gynecol Scand (2009) 0.92
Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey. Acta Obstet Gynecol Scand (2010) 0.90
Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. Am J Clin Pathol (2004) 0.90
Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. BJU Int (2011) 0.90
Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis. J Biol Chem (2013) 0.90
A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. Clin Chem (2010) 0.90
Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis. Mol Immunol (2009) 0.90
A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. J Biol Chem (2008) 0.90
Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer. Cancer Med (2014) 0.89
Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry. Int J Cancer (2011) 0.89
High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer (2008) 0.89
Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older. Cancer (2013) 0.89
Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor. Neoplasia (2012) 0.89
Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo. J Biol Chem (2008) 0.89
Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer. Scand J Clin Lab Invest (2010) 0.88
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. Thromb Haemost (2007) 0.88
Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies? APMIS (2012) 0.87